Fibronectin is an important regulator of flow-induced vascular remodeling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 7, 2009, Pages 1074-1079

  Chiang, Hou Yu ^a   Korshunov, Vyacheslav A ^a   Serour, Andrew ^a   Shi, Feng ^a   Sottile, Jane ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Collagen; Extracellular matrix; Fibronectin; Smooth muscle cell; Vascular remodeling

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; FIBRONECTIN INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; MYOSIN; PROTEIN INHIBITOR; PUR4 PEPTIDE; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKENING; ARTERY LIGATION; ARTICLE; BLOOD VESSEL PARAMETERS; BLOOD VESSEL WALL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EXTERNAL CAROTID ARTERY; EXTRACELLULAR MATRIX; IN VIVO CULTURE; INTERNAL CAROTID ARTERY; LYMPHOCYTIC INFILTRATION; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; VASCULAR REMODELING; ANIMAL; BLOOD RHEOLOGY; CAROTID ARTERY OBSTRUCTION; COMMON CAROTID ARTERY; DRUG ANTAGONISM; INJURY; INTIMA; PATHOPHYSIOLOGY; PHYSIOLOGY; SMOOTH MUSCLE FIBER; TUNICA MEDIA;

ANIMALS; CAROTID ARTERY, COMMON; CAROTID STENOSIS; FIBRONECTINS; HEMORHEOLOGY; MICE; MYOCYTES, SMOOTH MUSCLE; TUNICA INTIMA; TUNICA MEDIA;

EID: 67650281734     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.181081     Document Type: Article

References (51)

1. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell. 1996;87:1069 -1078.
2. Mercurius KW, Morla AO. Inhibition of vascular smooth muscle cell growth by inhibition of fibronectin matrix assembly. Circ Res. 1998;82:548-556.
3. Bourdoulous S, Orend G, MacKenna DA, Pasqualini R, Ruoslahti E. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J Cell Biol. 1998;143:267-276.
4. Sottile J, Hocking DC, Swiatek P. Fibronectin matrix assembly enhances adhesion-dependent cell growth. J Cell Sci. 1998;111:2933-2943.
5. Zhou X, Rowe RG, Hiraoka N, George JP, Wirtz D, Mosher DF, Virtanen I, Chernousov MA, Weiss SJ. Fibronectin fibrillogenesis regulates threedimensional neovessel formation. Genes Dev. 2008;22:1231-1243.
6. Sottile J, Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell. 2002;13:3546 -3559.
7. Sottile J, Shi F, Rublyevska I, Chiang HY, Lust J, Chandler J. Fibronectin-dependent collagen I deposition modulates the cell response to fibronectin. Am J Physiol Cell Physiol. 2007;293:C1934-C1946.
8. George EL, Georges-Labousse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Develop. 1993;119:1079 -1091.
9. George EL, Baldwin HS, Hynes RO. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood. 1997;90:3073-3081.
10. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581-587.
11. Strauss BH, Rabinovitch M. Adventitial fibroblasts: defining a role in vessel wall remodeling. Am J Respir Cell Mol Biol. 2000;22:1-3.
12. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001;81:999 -1030.
13. Pasterkamp G, de Kleijn DP, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res. 2000;45:843- 852.
14. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res. 2002;54:528 -538.
15. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation. 2001; 104:2815-2819.
16. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487-517.
17. Majesky MW. Neointima formation after acute vascular injury. Role of counteradhesive extracellular matrix proteins. Tex Heart Inst J. 1994;21: 78-85.
18. Korshunov VA, Berk BC. Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc Biol. 2003;23:2185-2191.
19. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17:2238 -2244.
20. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, Pauletto P. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89:1111-1121.
21. Hynes RO. Fibronectins. New York: Springer-Verlag; 1990.
22. McKeown-Longo PJ, Mosher DF. Interaction of the 70,000-mol-wt amino-terminal fragment of fibronectin with the matrix-assembly receptor of fibroblasts. J Cell Biol. 1985;100:364 -374.
23. Tomasini-Johansson BR, Kaugman NR, Ensenberger MG, Ozeri V, Hanski E, Mosher DF. Peptide from adhesin F1 inhibits fibronectin matrix assembly. J Biol Chem. 2001;276:23430 -23439.
24. Morla A, Zhang Z, Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature. 1994;367:193-196.
25. Ensenberger MG, Tomasini-Johansson BR, Sottile J, Ozeri V, Hanski E, Mosher DF. Specific interactions between F1 adhesin of Streptococcus pyogenes and N-terminal modules of fibronectin. J Biol Chem. 2001;276: 35606-35613.
26. DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA. Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol. 1993;122:729 -737.
27. Stringa E, White D, Tuan RS, Knauper V, Gavrilovic J. Role of newly synthesized fibronectin in vascular smooth muscle cell migration on matrixmetalloproteinase-degraded collagen. Biochem Soc Trans. 2002;30:102-111.
28. Hedin U, Bottger BA, Forsberg E, Johansson S, Thyberg J. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. J Cell Biol. 1988;107:307-319.
29. Korshunov VA, Berk BC. Strain-dependent vascular remodeling: the "Glagov phenomenon" is genetically determined. Circulation. 2004;110: 220-226.
30. Korshunov VA, Solomatina MA, Plekhanova OS, Parfyonova YV, Tkachuk VA, Berk BC. Plasminogen activator expression correlates with genetic differences in vascular remodeling. J Vasc Res. 2004;41:481-490.
31. Velling T, Risteli J, Wennerberg K, Mosher DF, Johansson S. Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1. J Biol Chem. 2002;277:37377-37381.
32. Rocnik EF, Chan BM, Pickering JG. Evidence for a role of collagen synthesis in arterial smooth muscle cell migration. J Clin Invest. 1998; 101:1889 -1898.
33. Hocking DC, Chang CH. Fibronectin matrix polymerization regulates small airway epithelial cell migration. Am J Physiol. 2003;285: L169-L179.
34. Sechler JL, Schwarzbauer JE. Control of cell cycle progression by fibronectin matrix architecture. J Biol Chem. 1998;273:25533-25536.
35. Kinsey R, Williamson MR, Chaudhry S, Mellody KT, McGovern A, Takahashi S, Shuttleworth CA, Kielty CM. Fibrillin-1 microfibril deposition is dependent on fibronectin assembly. J Cell Sci. 2008;121:2696-2704.
36. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. Anti-monocyte chemoattractant protein-1/ monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306 -314.
37. Clark RA, Wikner NE, Doherty DE, Norris DA. Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. J Biol Chem. 1988;263:12115-12123.
38. Norris DA, Clark RA, Swigart LM, Huff JC, Weston WL, Howell SE. Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J Immunol. 1982;129:1612-1618.
39. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA. The subendothelial extracellular matrix modulates NF-kappaB activation by flow: a potential role in atherosclerosis. J Cell Biol. 2005;169:191-202.
40. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol. 2002;22:5912-5922.
41. Ren L, Blanchette JB, White LR, Clark SA, Heffner DJ, Tibbles LA, Muruve DA. Soluble fibronectin induces chemokine gene expression in renal tubular epithelial cells. Kidney Int. 2005;68:2111-2120.
42. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344 -362.
43. Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res. 1999;250:273-283.
44. Moura R, Tjwa M, Vandervoort P, Cludts K, Hoylaerts MF. Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation. Arterioscler Thromb Vasc Biol. 2007;27:2163-2169.
45. Dufourcq P, Couffinhal T, Alzieu P, Daret D, Moreau C, Duplaa C, Bonnet J. Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation. Cardiovasc Res. 2002;53:952-962.
46. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol. 1997;17:188 -193.
47. Li YH, Liu SL, Shi GY, Tseng GH, Liu PY, Wu HL. Thrombomodulin plays an important role in arterial remodeling and neointima formation in mouse carotid ligation model. Thromb Haemost. 2006;95:128 -133.
48. Myers DL, Harmon KJ, Lindner V, Liaw L. Alterations of arterial physiology in osteopontin-null mice. Arterioscler Thromb Vasc Biol. 2003;23:1021-1028.
49. Schiffers PM, Henrion D, Boulanger CM, Colucci-Guyon E, Langa-Vuves F, van Essen H, Fazzi GE, Levy BI, De Mey JG. Altered flow-induced arterial remodeling in vimentin-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:611- 616.
50. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203-2206.
51. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes DR Jr, Schwartz RS, Mousa SA. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alphav beta3 and osteopontin expression during neointima formation. Cardiovasc Res. 1997;36:408-428.